|
業務類別
|
-- |
|
業務概覽
|
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, whichis being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes. |
| 公司地址
| Sydmarken 11, Soborg, DNK, DK-2860 |
| 電話號碼
| +45 88773600 |
| 傳真號碼
| +45 88773898 |
| 公司網頁
| https://www.zealandpharma.com |
| 員工數量
| 501 |
| Ms. Henriette Wennicke |
Executive Vice President and Chief Financial Officer |
-- |
19/02/2026 |
| Mr. Adam Steensberg |
President and Chief Executive Officer |
-- |
19/02/2026 |
|
|
| Dr. Elaine Sullivan, PhD |
Independent Director |
19/02/2026 |
| Mr. Leonard Kruimer |
Independent Director |
19/02/2026 |
| Dr. Martin Nicklasson, PhD |
Chairman of the Board |
19/02/2026 |
| Dr. Ludovic Tranholm Otterbein, PhD |
Director |
19/02/2026 |
| Mr. Jeffrey Berkowitz |
Independent Director |
19/02/2026 |
| Dr. Kirsten A. Drejer |
Vice Chairman of the Board |
19/02/2026 |
| Ms. Bernadette M. Connaughton |
Independent Director |
19/02/2026 |
| Mr. Adam Krisko Nygaard |
Director |
19/02/2026 |
| Mr. Frederik Barfoed Beck |
Director |
19/02/2026 |
| Mr. Enrique Conterno |
Independent Director |
19/02/2026 |
| Ms. Anneline Nansen |
Director |
19/02/2026 |
|
|
|
|
